"Myasthenia Gravis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
| Descriptor ID |
D009157
|
| MeSH Number(s) |
C10.114.656 C10.668.758.725 C20.111.258.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myasthenia Gravis".
Below are MeSH descriptors whose meaning is more specific than "Myasthenia Gravis".
This graph shows the total number of publications written about "Myasthenia Gravis" by people in this website by year, and whether "Myasthenia Gravis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 5 | 0 | 5 |
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myasthenia Gravis" by people in Profiles.
-
Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol. 2022 Oct 01; 28(7):367-373.
-
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. Oncologist. 2021 12; 26(12):1052-1061.
-
Modulation of immune responses by bile acid receptor agonists in myasthenia gravis. J Neuroimmunol. 2020 12 15; 349:577397.
-
ATM mutation in a patient with thymoma-associated myasthenia gravis. Muscle Nerve. 2020 08; 62(2):E50-E52.
-
Myasthenia gravis induced by avelumab. Immunotherapy. 2019 10; 11(14):1181-1185.
-
Head-drop: A frequent feature of late-onset myasthenia gravis. Muscle Nerve. 2017 09; 56(3):441-444.
-
Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016 Jul; 107(7):1055-8.
-
Impaired regulatory B cells in myasthenia gravis. J Neuroimmunol. 2016 08 15; 297:38-45.
-
Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia. Clin Genet. 2014 Feb; 85(2):166-71.
-
A sodium channel myotonia due to a novel SCN4A mutation accompanied by acquired autoimmune myasthenia gravis. Neurosci Lett. 2012 Jun 21; 519(1):67-72.